The present study reports the results of an open-label trial on the use of the combination of olanzapine (an atypical antipsychotic) + serotonin reuptake inhibitors (SRIs) in 26 resistant outpatients affected by resistant obsessive-compulsive disorder (OCD). All patients had been suffering from OCD, according to DSM IV criteria, for at least 2 years and had different comorbid disorders; they had been treated with an SRI at adequate dosages for at least 6 months, or had tried different augmentation strategies with no or poor response. As a result, olanzapine was added and continued for 1 year. After 12 weeks of this regimen, most of the patients (17) had shown a reduction in OC symptoms, as assessed by a decrease in the Yale-Brown Obsessive Compulsive Scale total score, which continued throughout subsequent months. Only mild side-effects were recorded and no patient halted the treatment. The addition of olanzapine would appear to be a useful short- and long-term strategy for augmenting SRI effectiveness in resistant OCD patients, especially in those presenting comorbidity with bipolar disorders.
Augmentation strategy with olanzapine in resistant obsessive compulsive disorder : an Italian long-term open-label study / D. Marazziti, C. Pfanner, B. Dell'Osso, A. Ciapparelli, S. Presta, G. Corretti, E. Di Nasso, F. Mungai, L. Dell'Osso. - In: JOURNAL OF PSYCHOPHARMACOLOGY. - ISSN 0269-8811. - 19:4(2005), pp. 392-394.
Augmentation strategy with olanzapine in resistant obsessive compulsive disorder : an Italian long-term open-label study
B. Dell'Osso;
2005
Abstract
The present study reports the results of an open-label trial on the use of the combination of olanzapine (an atypical antipsychotic) + serotonin reuptake inhibitors (SRIs) in 26 resistant outpatients affected by resistant obsessive-compulsive disorder (OCD). All patients had been suffering from OCD, according to DSM IV criteria, for at least 2 years and had different comorbid disorders; they had been treated with an SRI at adequate dosages for at least 6 months, or had tried different augmentation strategies with no or poor response. As a result, olanzapine was added and continued for 1 year. After 12 weeks of this regimen, most of the patients (17) had shown a reduction in OC symptoms, as assessed by a decrease in the Yale-Brown Obsessive Compulsive Scale total score, which continued throughout subsequent months. Only mild side-effects were recorded and no patient halted the treatment. The addition of olanzapine would appear to be a useful short- and long-term strategy for augmenting SRI effectiveness in resistant OCD patients, especially in those presenting comorbidity with bipolar disorders.File | Dimensione | Formato | |
---|---|---|---|
marazziti, pfanner et al, 2005.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
270.07 kB
Formato
Adobe PDF
|
270.07 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.